Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

TOKYO, May 17, 2012 /PRNewswire/ --

  • GLOW2 study showed NVA237 superior to placebo and similar to OL tiotropium in increasing lung function, improving COPD symptoms and reducing exacerbations
  • Results demonstrated that once-daily NVA237 had rapid onset of action at first dose, sustained 24-hour bronchodilation, and was well tolerated over 52 weeks
  • NVA237 submitted forEU approval under proposed brand name Seebri® Breezhaler®. CHMP decision anticipated in 2012. In Japan, NDA submitted in November 2011. US filing expected in 2014

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) confirms the information released today by Novartis that results from the pivotal Phase III GLOW2 study demonstrated that once-daily (QD) 50 mcg NVA237 (glycopyrronium bromide) was superior to placebo in improving lung function, symptom relief and quality of life, and reducing exacerbations over a one-year period. The data will be presented at the 2012 American Thoracic Society (ATS) International Conference May 18-23, 2012 in San Francisco, CA, USA.

GLOW2 met its primary endpoint by demonstrating NVA237 provided superior 24-hour bronchodilation compared to placebo at 12 weeks measured by mean trough FEV1 (97 mL; p<0.001). At this same time point, trough FEV1 for open-label (OL) tiotropium was 83 mL versus placebo (p<0.001). In addition, NVA237 showed similar efficacy to OL tiotropium (Spiriva® HandiHaler®* Spiriva® HandiHaler® is a registered trademark by Boehringer Ingelheim Pharma Gmbh & Co. KG.
/18 mcg) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). NVA237 also demonstrated rapid onset of action (within five minutes at first dose) and su
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014 /PRNewswire-iReach/ -- ... the basis of products, methods, applications, end users, ... highest growth in the microbial identification market. This ... consumable costs (per test) and the time required ... and continuous technological advancements. Furthermore, genotypic methods have ...
(Date:7/29/2014)... Inc. (NASDAQ: SQNM ), a life sciences ... revenues of $39.8 million for the second quarter of ... $24.5 million for the second quarter of 2013. ... on May 30, 2014, has been accounted for as ... excluded from continuing operations for all periods. ...
(Date:7/29/2014)... , July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... participating in two healthcare conferences during the third quarter, ... Morgan Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation ... The details on each event are below: ... 11, 2014 in Boston , MA.  ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3
... Sept. 28 Tamir Biotechnology, Inc. (Pink Sheets: ... today that scientists supported by the National Institute ... results confirming two of our lead compounds outperformed ... and plaque reduction assay (the gold standard) for ...
... Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available... -- DALLAS, September 28, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 2Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 3Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 5Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 6Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 7Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 8Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 9
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip reveals ... created by a holistic nutritional and functional medicine practitioner, who ... overcoming this problem. , Karen suffered from leaky gut, too, ... time to develop this unique treatment. , Karen Brimeyer ... with sufferers from all around the world. The author of ...
(Date:7/29/2014)... 2014 Parker Waichman LLP, a national ... injured by defective drugs and medical devices, reports that ... in Canada who allege that they were never warned ... the low testosterone injection Delatestryl (Court File No. 3704CP/14). ... the Ontario Superior Court of Justice. , “Testosterone lawsuits ...
(Date:7/29/2014)... Daily Gossip reveals in its review that the ... will permanently eliminate all the symptoms associated to this condition. ... banish symptoms such as mild hearing loss, as well as ... will be gone forever. , The method will lead to ... this program says that at the end of the treatment, ...
(Date:7/29/2014)... -- Want young children to embrace a more healthful ... good for them. Doing so will actually make them ... "Parents and caregivers who are struggling to get ... serving the food without saying anything about it, or ... said study authors Michal Maimaran, of Northwestern University,s Kellogg ...
(Date:7/29/2014)... Randy Dotinga HealthDay Reporter ... When most children take on a task, various brain ... neuro-boosting activity in kids with autism, according to a ... symptoms of autism displayed even less of this "brain ... flexibility often causes difficulty when children with autism are ...
Breaking Medicine News(10 mins):Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3
... , THURSDAY, May 12 (HealthDay News) -- Heart ... high level of health literacy are more likely to continue ... with low health literacy, a new study finds. Health ... health care information. Telemonitoring systems, which help doctors monitor patients ...
... been "seizing" uncontrollably. Now a Tel Aviv University researcher ... with the uncontrolled spasms of an epileptic is not ... of the disaster. In a recent article published ... Tel Aviv University,s School of Physics and Astronomy, his ...
... HealthDay Reporter , THURSDAY, May 12 (HealthDay News) ... they are lactose-intolerant may actually suffer from a psychological ... intolerance, a person is deficient in the enzyme lactase, ... say they experience bloating, gas, gut pain and nausea ...
... News) -- Mind-body therapies such as yoga, meditation and deep-breathing ... according to a new study. Mind-body therapy is ... is rising, the researchers noted. They found that one in ... to the treatment by a medical provider. "There,s good ...
... 12, 2011 -- The American College of Physicians (ACP) ... and ACP InternistWeekly have won awards for excellence in ... from Association Media & Publishing in the Newspapers: Feature ... remote monitoring and a silver award for Best How-To ...
... German . , Neural stem cells can do a lot, ... not usually generated by neural stem cells of the peripheral nervous ... peripheral nervous system from the stem cells of the brain. However, ... and the Max Planck Institute of Immunobiology and Epigenetics in Freiburg ...
Cached Medicine News:Health News:Telemonitoring Success May Depend on Patients' Age, Literacy Level 2Health News:Diagnosing 'seizures' in the US economy 2Health News:Lactose Intolerance May Sometimes Be in the Head, Not the Gut 2Health News:Doctors Prescribing Meditation, Yoga More Often 2Health News:A new program for neural stem cells 2Health News:A new program for neural stem cells 3
... full PIP joint or DIP joint flexion ... arthritic changes. Unparalleled in comfort and softness, ... to prevent slipping and allows for infinite ... in packages of 5 and boxes of ...
... Oval-8 Ring Splints provide finger stability ... acute injuries, hypermobility, and loss of control ... splints are made from translucent, neutral-tone plastic ... The 3-point pressure design makes them the ...
... Immobilizer is made of lightweight aluminum posterior, ... foam material that wicks moisture away from ... of the splint is uniquely tailored for ... and lock closure straps allow for optimum ...
... Neuroprene™ soft supports are a ... to proprioceptive taping for common orthopedic ... help provide specific compression and lateral ... receptors (proprioceptors) in the skin and ...
Medicine Products: